February 21, 2007 – InSightec’s ExAblate 2000, a Magnetic Resonance Imaging (MRI) focused ultrasound device that treats uterine fibroid tumors, is now allowing most patients to find relief within three months of treatment and to return to work within days.
The ExAblate 2000 uses a combination of ultrasound waves and MRIs to image, treat and ablate soft tissue. Treatment typically takes about three or four hours.
July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...
July 25, 2024 
July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...
July 23, 2024 
July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...
July 23, 2024 
July 19, 2024 — GE HealthCare announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s ...
July 19, 2024 
July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...
July 17, 2024 
July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...
July 11, 2024 
Investing in women’s health should not merely be a metric on the equity dashboard — it should drive policy and tactical ...
July 08, 2024 
July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...
July 02, 2024 
June 27, 2024 — Prenuvo, which makes whole-body MRI screening for early cancer detection and other diseases, has ...
June 27, 2024 
June 25, 2024 — Rady Children’s Hospital-San Diego, one of the nation’s top pediatric health care systems, today ...
June 25, 2024